Last Updated on December 31, 2023 by The Health Master
Drug firm Laurus Labs on Friday said it has received the licence from Defence Research and Development Organisation to manufacture and market C-19 treatment drug 2-Deoxy-D-Glucose (2DG).
2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on C-19 patients in the country, Laurus Labs said in a regulatory filing.
“Laurus Labs has already applied with the Central Drugs Standard Control Organisation (CDSCO) for emergency use authorization (EUA) for 2DG,” it added.
On June 28, pharma major Dr Reddy’s announced the commercial launch of 2DG at a maximum retail price of Rs 990 per sachet.
Shares of Laurus Labs were trading at Rs 674.20 per scrip on BSE, up 1.08 per cent from the previous close.
Alembic gets USFDA nod for Nitrofurantoin Capsules USP
Axio Biosolution gets USFDA nod for Patch for bleeding control
Glenmark gets USFDA nod for generic Lung cancer drug
USFDA okays Tocilizumab for treatment of Covid-19
Zydus Cadila gets tentative nod from USFDA for Pemetrexed for Injection
Cipla gets USFDA nod for Inhalation product
172 Drug Inspectors appointed as Medical Device Officer
These 5 Pharma giants join hands to test oral C-19 drug
DCGI denied approval for final trial of Sputnik Light to Dr…
NPPA fixes retail prices of 3 formulations
DCGI allows Cipla to import Moderna vaccine in India
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
